Showing 1–25 of 40 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, et al.
…nd other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB). Methods The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-T…
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
…TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been …
Tushar R. Sahasrabudhe
…tional TB Elimination Programme (NTEP) has fixed 2HREZ/4HRE regimen for all drug-sensitive (DS-TB) cases, comprising of isoniazid (H), rifampicin (R), ethambutol (E), and pyrazinamide (Z). These potent first-line drugs, i.e., HREZ, are the backbone of DS-TB treatment for last man…
Rivaldo Heru Setiawan
…lobal public health challenge, with multidrug-resistant TB (MDR-TB) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, …
Tari Nur Fauziyantini, Umi Yuniarni, Lanny Mulqie
…especially in the case of Multidrug-Resistant Tuberculosis (MDR-TB). This study aims to examine the TB-RO therapy regimen that applies in Indonesia through a descriptive analysis approach. The research process was carried out by searching, selecting and analyzing scientific liter…
Serisha Ramasir, Frasia Oosthuizen, Varsha Bangalee
… of said guidelines. The multi-drug resistant tuberculosis (MDR-TB) guideline has undergone major changes over the past 5 years. These changes included shorter treatment regimens and the introduction of novel drugs. These changes have consequently impacted the management of MDR-T…
Piamlarp Sangsayunh, Thanyanuch Sanchat, Charoen Chuchottaworn, Krisana Cheewakul, Sirijit Rattanawai
…nges associated with the implementing of the groundbreaking BPaL-containing regimen in Thailand. Another aim was to investigate the characteristics and severity of the disease, the presence of abnormal extensive lesions in chest X-Rays and the influence of cavitation on sputum co…
Filipa Mota, Camilo A. Ruiz-Bedoya, Elizabeth W. Tucker, Patricia De Jesus, Kelly Flavahan, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Mota F, Ruiz-Bedoya C, Tucker E, De Jesus P, Flavahan K, et al.
…anid is used in combination with bedaquiline and linezolid (BPaL regimen) in the treatment of multidrug-resistant tuberculosis (MDR-TB). However, the penetration of pretomanid in privileged sites remain unknown. Antimicrobial pharmacokinetic (PK) parameters are traditionally deri…
Rajendra Prasad, Harsh Saxena, Nikhil Gupta, Mohammad Tanzeem, Ronal Naorem1
… of DR-TB with or without newer anti-TB drugs. multi-DR-TB (MDR-TB) patients have now choice of two types of regimen, shorter and longer regimens. Shorter regimen for treatment of subset of MDR-TB patients who have not been previously treated with second line drugs and in whom re…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Y. I. Feshchenko, N.А. Lytvynenko, L.M. Protsyk, M.V. Pohrebna, Yu.О. Senko
BACKGROUND. Six-month short-term treatment regimens for drug-resistant tuberculosis (DR-TB) are more effective and better tolerated compared to longer regimens. There is a need to develop a clear algorithm for their prescription. OBJECTIVE. To develop a clinical algorithm for sel…
Kavitha Saravu, Madhukar Pai
…ant TB (RR-TB), and 82% of them had multidrug-resistant TB (MDR-TB); 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB. A quarter of the DR-TB cases globally were from India.[1] Only about 25% of these estimated MDR-TB or RR-TB were diagnosed and notified. Th…
Christian Tague
HIV coinfection and multidrug-resistant tuberculosis (MDR-TB) pose a major public health challenge in sub-Saharan Africa, where high HIV prevalence promotes tuberculosis progression and complicates its management. In people living with HIV (PLHIV), profound immunosuppression lead…
Oki Nugraha Putra, Telly Purnamasari
…red either a shorter (9 months) or individualized treatment regimen (18 months). However, long treatment duration with various adverse events affects patient compliance. Therefore, a short treatment with less medication is urgently required. In 2022, the WHO announced an alternat…
Tushar Garg
…reatments for complicated multidrug-resistant tuberculosis (MDR-TB) and extensive drug-resistant tuberculosis (XDR-TB), it will be challenging to achieve the World Health Organization (WHO) goal to end the global TB epidemic by 2035. The treatment of MDR- and XDR-TB consists of 4…
Carlos Acuña-Villaorduña, Karen R. Jacobson, C. Robert Horsburgh, Martin Canning, Pranay Sinha
Initial experience with BPaL-based regimens to treat multidrug-resistant TB Dear Editor, We read with interest the recent article on the latest WHO guidelines on drug-resistant TB. 1 The recommendation to implement all-oral regimens containing bedaquiline, pretomanid and linezoli…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed the risk factors for unfavorable outcomes (death, treatment failure, and…
Zarir F Udwadia, Jigneshkumar M. Patel
…ease in the number of cases of TB and multi-drug resistant (MDR-TB) has unravelled decades of progress and reflects the profound impact COVID-19 has had on tuberculosis. Despite this grim news, these are exciting times for doctors treating Drug Resistant TB (DR-TB) and for their …
Girase R, Ahmad I, Patel H
…against M. tuberculosis and is a crucial constituent of the BPaL regimen (Bedaquiline, Pretomanid, and Linezolid), which was authorized by the FDA in 2019 for the treatment of XDR-TB or MDR-TB. Despite its unique mechanism of action, Linezolid carries a considerable risk of toxic…
George Ikpe, Shadrach Dimang, Ufuoma Aduh, Peter Idowu Omoniyi, Ugochukwu Chukwulobelu, et al.
…CTION:** the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, …
Marco Schiuma, Souleymane Hassane Harouna
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023. Only 44% were diagnosed and put on treatment, the therapeutic success rat…
Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, et al.
…ew treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in t…
Rafael Laniado-Laborı́n
…l or molecular tests for standardized drug sensitivity. Any regimen for drug-resistant TB is more likely to be effective if its composition is based on information from reliable drug susceptibility testing. The presence of drug-resistant tuberculosis should be suspected in patien…
Bruning-Barry R, Ambroso JL, Dillberger J, Yang TJ
…in more than 10 countries as part of a three-drug, all oral regimen, consisting of bedaquiline, pretomanid, and linezolid (BPaL) for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis (XDR-TB) or with complicated forms of multidrug-resistant tuber…